Table 3 The relationship between clinico-pathological stages of gastric cancer and P-gp, MRP and LRP
| Â | Â | Positive rates of MDR proteins | ||
|---|---|---|---|---|
Stages | Numbers n(%) | P-gp* n(%) | MRP n(%) | LRP n(%) |
TNM stages | Â | Â | Â | Â |
T2 | 13 (22.0) | 12 (92.3) | 6 (46.2) | 10 (76.9) |
T3 | 44 (74.6) | 37 (84.1) | 10 (22.7) | 39 (88.6) |
T4 | 2 (3.4) | 2 (100) | 0 (0.0) | 1 (50.0) |
N0 | 24 (40.7) | 21 (87.5) | 10 (41.7) | 21 (87.5) |
N1 | 18 (30.5) | 14 (77.8) | 2 (11.1) | 15 (83.3) |
N2 | 15 (25.4) | 14 (93.3) | 3 (20.0) | 12 (80.0) |
N3 | 2 (3.4) | 2 (100) | 1 (50.0) | 2 (100.0) |
M0 | 57 (96.6) | 49 (86.0) | 16 (28.1) | 49 (86.0) |
M1 | 2 (3.4) | 2 (100.0) | 0 (0.0) | 1 (50.0) |
Clinical stages | Â | Â | Â | Â |
IB | 10 (16.9) | 10 (100) | 6 (60.0) | 9 (90.0) |
II | 13 (22.0) | 10 (76.9) | 4 (30.8) | 11 (84.6) |
IIIA | 18 (30.5) | 14 (77.8) | 2 (11.1) | 16 (88.9) |
IIIB | 14 (23.7) | 13 (92.9) | 3 (21.4) | 12 (85.7) |
IV | 4 (6.8) | 4 (100) | 1 (25.0) | 2 (50.0) |